CytoDyn obtains IRB approval for leronlimab for patients with TNBC
Category: #health  By Mateen Dalal  Date: 2019-11-13
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

CytoDyn obtains IRB approval for leronlimab for patients with TNBC

Reports confirm that CytoDyn Inc., a late-stage biotechnology company has announced that it has recently received approval from the Institutional Review Board for leronlimab, to be directed to triple-negative breast cancer (TNBC) patients under a compassionate use, which is also called expanded access program.

Apparently, this program will enable TNBC patients who are not entitled under the current Phase 1b/2 clinical trial to get leronlimab (PRO 140). Patients with locally recurrent or metastatic TNBC who had improved within 6 months or less on advanced chemotherapy will get leronlimab combined with a physician recommended treatment.

Seemingly, the expanded access program is a potential way for patients with an instantly life-threatening condition to gain access to an investigational medical product for treatment outside of medical trials, when no other satisfactory therapy options are available. An Institutional Review Board (IRB) is a suitably constituted group that has been officially designated to review and examine biomedical research including human subjects in accordance with regulation of the U.S. Food and Drug Administration.  

According to President and Chief Executive Officer of CytoDyn, Nader Pourhassan (Ph.D.,), the IRB has given access to leronlimab for patients with triple-negative breast cancer. The company is looking to advance this treatment opportunity to various patients in the current trials.

The U.S. Food and Drug Administration has reportedly approved a “Fast Track” label to CytoDyn for two prospective indications of leronlimab for lethal diseases. The first as a combination therapy with extremely active anti-retroviral therapy for HIV-infected patients, and the second one is for metastatic triple-negative breast cancer.

If sources are to be believed, leronlimab has successfully finished nine clinical trials in more than 800 people, including meeting its key endpoints in a vital Phase 3 trial.

For the uninitiated, CytoDyn is a biotechnology company developing advanced treatments for several therapeutic indications based on leronlimab.

 

Source Credits: https://www.cytodyn.com/newsroom/press-releases/detail/360/cytodyn-receives-irb-approval-to-proceed-with-compassionate

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

China unveils plans to reinforce stringent safety standards for EVs

China unveils plans to reinforce stringent safety standards for EVs

By Mateen Dalal

This news comes amid rising incidences of battery fires and breaks failures. China will require automakers to have a 24-hour emergency response system to address major accidents. China is planning to reinforce strict safety standards for electri...

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...